CliffBio
small molecule

KIMYRSA

ORITAVANCIN DIPHOSPHATE

Loss of exclusivityJuly 2035latest FDA-listed patent expiry
CompanyMelinta Therapeutics →View the full company profile on CliffBio

Drug detail

Brand nameKIMYRSA
Active ingredientORITAVANCIN DIPHOSPHATE
StrengthEQ 1.2GM BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2021
Marketing statusRX

Listed patents

PatentExpiresType
9649352July 2035substance, product
9682061April 2030use U-3101
12514899August 2029use U-4398
8420592August 2029use U-3101

More from Melinta Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KIMYRSA patent cliff — loss of exclusivity July 2035 | CliffBio